Thyroid (desiccated)

Armour Thyroid is porcine desiccated thyroid extract containing T4 and T3. The current label and FDA identify animal-derived thyroid products as unapproved. DailyMed listing, prescription availability and longstanding use do not establish FDA approval or equivalence to approved levothyroxine.

The unapproved Armour label describes thyroid replacement for hypothyroidism, excluding transient recovery-phase subacute thyroiditis, and TSH suppression for certain goiters/cancers. These are label statements, not FDA-approved indications or a recommendation to suppress TSH in every nodule. ATA recommends levothyroxine as routine first-line replacement; selected DTE therapy requires individualized discussion.

FDA’s current page and August 5,2026 notice describe interim risk-based enforcement while guidance/development pathways are being worked on. This does not establish approval, a new DTE formulation, or a blanket market-removal date. Discuss treatment options with the prescriber; do not abandon necessary hormone replacement.

The current unapproved product label describes a usual start of 30 mg/day, increasing by 15 mg every 2–3 weeks according to response/cardiovascular status. It describes 15 mg/day for longstanding myxedema, particularly when cardiovascular impairment is suspected, and usual maintenance 60–120 mg/day. Angina warrants dose review/reduction. These are product-label summaries, not a universal starting prescription.

One Armour grain is 60 mg extract with 38 mcg T4 and 9 mcg T3. Do not treat 60 mg extract as 60 mg pure thyroid hormone or equate its hormone content to a levothyroxine-only daily dose. Actual titration depends on thyroid tests, symptoms, indication, cardiac risk and the selected product.

The retained Armour label prints the following congenital-hypothyroidism table. It is presented as unapproved label content, not a first-line pediatric protocol. ATA pediatric guidance uses levothyroxine; congenital disease requires prompt pediatric endocrine treatment. The age amounts and weight amounts are both source columns and must not be combined or independently used to override a specialist dose.

Use a consistent prescribed administration routine and reassess absorption/adherence after unexpected tests or a product change. Fasting can improve absorption; the Armour label does not establish a modern product-specific 30–60-minute meal rule. No validated CrCl/hepatic-adjustment formula is provided. Older/cardiac patients need cautious dosing, and central hypothyroidism cannot be titrated using TSH alone.

Cancer-related suppression needs a disease-specific specialist target; no universal suppression dose is supplied here. Myxedema coma is an emergency requiring hospital treatment and separate injectable thyroid hormone management, not a home Armour escalation. The label’s older IV levothyroxine discussion is not an Armour formulation or conversion regimen.

The label lists uncorrected adrenal cortical insufficiency, untreated thyrotoxicosis and apparent hypersensitivity to active/extraneous constituents. Avoid assuming every pork-food allergy predicts the same reaction, or that the label’s statement about rarity of true hormone allergy eliminates excipient/source assessment.

The current unapproved label contains a boxed warning against using thyroid hormone for obesity/weight loss: replacement-range doses do not produce effective weight loss in euthyroid patients, and larger doses can cause life-threatening toxicity, especially with sympathomimetic agents. The box’s presence does not mean FDA approved the product labeling.

The product label primarily describes adverse effects of therapeutic overdosage resembling hyperthyroidism, including cardiovascular/CNS/metabolic symptoms. Partial hair loss in children may be transient early in therapy. Long-term excess hormone poses cardiac/skeletal concerns; no unsupported frequency estimate or comparative safety advantage is claimed.

Thyroid replacement can increase sensitivity to oral anticoagulants; follow INR/prothrombin response and adjust the anticoagulant clinically. Glucose-lowering needs may increase as replacement is achieved and change again if therapy stops; monitor actual glucose control rather than apply a fixed insulin change.

Cholestyramine/colestipol bind both T4 and T3; the Armour label recommends 4–5 hours between them and thyroid hormone. Review iron, calcium and other binding agents with the prescriber/pharmacist; guidance on thyroid-hormone absorption does not establish automatic interchangeability of DTE and levothyroxine.

Estrogens/estrogen-containing contraceptives raise thyroxine-binding globulin and can alter replacement requirements. Androgens, corticosteroids, salicylates and other agents can affect binding/test interpretation. Evaluate free hormone when total values are misleading; do not infer a new dose from a binding-protein change alone.

The label instructs stopping biotin-containing supplements at least 2 days before thyroid tests because certain assays can give erroneous results. Follow laboratory instructions when longer holds are needed. Sympathomimetic weight-loss combinations increase toxicity risk and are not an appropriate use of thyroid replacement.

Although the Armour label broadly includes pregnancy among replacement populations, ATA guidance recommends against continuing/starting DTE or T3 preparations for maternal hypothyroidism because fetal T4 delivery matters. Contact the clinician promptly for a levothyroxine-based plan and testing; do not abruptly stop necessary replacement while arranging care.

The label reports minimal thyroid hormone in milk and advises caution. Adequate maternal replacement remains clinically important; use an individualized product choice and monitoring plan rather than assume the DTE source or a low transfer statement proves safety superiority.

Congenital hypothyroidism needs rapid, specialist-guided treatment; the Armour table does not supersede levothyroxine pediatric practice. Older/cardiac patients require low-dose caution. In pituitary/hypothalamic disease, free T4 and clinical assessment are important because TSH can be unreliable.

The reviewed Armour label gives no product-specific renal or hepatic dose table. Binding-protein changes, nephrotic hormone loss, other illnesses and cardiac risk can complicate tests/requirements. Do not transplant a levothyroxine-only no-adjustment rule into an untested universal DTE regimen.

Thyroid hormones affect gene regulation, metabolism and development. T4 also provides a precursor for peripheral T3 production. Armour’s 38: 9 microgram content gives a T4:T3 ratio about 4.2: 1; ATA discusses a higher T3 proportion than human thyroid secretion and resultant peak/excess concerns. No clinical superiority follows from containing both hormones.

The label describes incomplete variable T4 absorption, relatively rapid T3 absorption, extensive circulating protein binding, and deiodination/conjugation with enterohepatic handling. These hormone-level observations do not constitute a modern product-specific bioequivalence study for every DTE tablet or brand.

ATA’s 2025 statement recognizes individualized patient preferences while retaining levothyroxine as standard therapy. The guideline identifies limited controlled long-term DTE safety/outcome evidence. Do not turn short-term preference data into a claim of established long-term safety or a validated genetic indication.

Assess thyroid tests and symptoms together, with cardiac status, diabetes/anticoagulant response and adherence/absorption context. Primary disease generally uses TSH; central disease requires free-T4 assessment. The Armour label describes reassessment within the first 4 weeks; timing and targets should be individualized rather than promise every patient normalizes in 2–3 weeks.

Replacement may be lifelong. Report chest pain, tachycardia, palpitations, marked heat intolerance or nervousness. Keep the same verified product/routine until a planned change, disclose biotin and interacting medicines, and arrange follow-up after switches. Pregnancy planning should be discussed before conception.

Review actual manufacturer/strength/lot with the pharmacist if potency or supply concerns arise. FDA status concerns do not prove every brand/lot has the same defect. This profile is not a real-time recall clearance; continue clinically necessary replacement while seeking professional instructions.

Armour 60 mg (1 grain) is a light-tan round tablet with an A/mortar-and-pestle motif and strength code TE; 100-count NDC 0456-0459-01. The current March 2024 label is distributed by AbbVie and expressly states it has not been approved as a new drug by FDA.

Oral Armour tablets: 15, 30, 60, 90, 120, 180, 240 and 300 mg, corresponding to ¼, ½, 1, 1½, 2, 3, 4 and 5 grains. Each Armour 60 mg tablet provides 38 mcg T4 and 9 mcg T3. Other DTE brands/salts may use different grain mass conventions; this profile verifies Armour, not every animal-derived product.

Store in a tight container protected from light/moisture at 15–30°C. Keep securely away from children. A characteristic extract odor is described by the label but does not replace package integrity/expiration checks.